Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective, Randomized, Adaptive Phase II/III Clinical Trial, Controlled, Open-label, 3-arms, Parallel, Multi-centred, Chemoprevention of COVID-19: Hydroxychloroquine Post Exposure Prophylaxis For COVID-19

NCT04597775 is registered in ClinicalTrials.gov with Regional Center for Disease Control and Prevention, Jordan as lead sponsor.

NCT NCT04597775
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04597775 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective, Randomized, Adaptive Phase II/III Clinical Trial, Controlled, Open-label, 3-arms, Parallel, Multi-centred, Chemoprevention of COVID-19: Hydroxychloroquine Post Exposure Prophylaxis For COVID-19
Lead sponsor
Regional Center for Disease Control and Prevention, Jordan
Phase
Phase 2/3
Overall status
Unknown status
Start date
October 27, 2020
Completion date
January 31, 2021
Enrollment
93 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

sars-cov infection